RU2004116473A - Производные пиридина в качестве блокаторов подтипа nmda- рецепторов - Google Patents
Производные пиридина в качестве блокаторов подтипа nmda- рецепторов Download PDFInfo
- Publication number
- RU2004116473A RU2004116473A RU2004116473/04A RU2004116473A RU2004116473A RU 2004116473 A RU2004116473 A RU 2004116473A RU 2004116473/04 A RU2004116473/04 A RU 2004116473/04A RU 2004116473 A RU2004116473 A RU 2004116473A RU 2004116473 A RU2004116473 A RU 2004116473A
- Authority
- RU
- Russia
- Prior art keywords
- formula
- compounds
- ylamine
- compound
- dihydronaphthalen
- Prior art date
Links
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 title claims 3
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 title claims 3
- 150000003222 pyridines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 40
- 150000003839 salts Chemical class 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 230000004770 neurodegeneration Effects 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 208000002193 Pain Diseases 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 4
- 230000001684 chronic effect Effects 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 230000003993 interaction Effects 0.000 claims 4
- -1 3,4-dihydronaphthalen-2-yl Chemical group 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- VXARDGMDMUMINC-UHFFFAOYSA-N 2-(2-phenylethenyl)pyridin-3-amine Chemical compound NC1=CC=CN=C1C=CC1=CC=CC=C1 VXARDGMDMUMINC-UHFFFAOYSA-N 0.000 claims 2
- WLDMSTVZYSHYAN-UHFFFAOYSA-N 4-(2-phenylethenyl)pyridin-2-amine Chemical compound C1=NC(N)=CC(C=CC=2C=CC=CC=2)=C1 WLDMSTVZYSHYAN-UHFFFAOYSA-N 0.000 claims 2
- VZOYVGQAPOCCMI-UHFFFAOYSA-N 6-(2-phenylethenyl)pyridin-2-amine Chemical compound NC1=CC=CC(C=CC=2C=CC=CC=2)=N1 VZOYVGQAPOCCMI-UHFFFAOYSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 2
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 208000005298 acute pain Diseases 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims 2
- 208000029028 brain injury Diseases 0.000 claims 2
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- BALMNUYDNZTRGL-UHFFFAOYSA-N 2-(3,4-dihydronaphthalen-2-yl)-6-methylpyridin-4-amine Chemical compound CC1=CC(N)=CC(C=2CCC3=CC=CC=C3C=2)=N1 BALMNUYDNZTRGL-UHFFFAOYSA-N 0.000 claims 1
- KGFGDIMGKWUXPR-UHFFFAOYSA-N 2-(3,4-dihydronaphthalen-2-yl)pyridin-4-amine Chemical compound NC1=CC=NC(C=2CCC3=CC=CC=C3C=2)=C1 KGFGDIMGKWUXPR-UHFFFAOYSA-N 0.000 claims 1
- SNKWOEPQIIAWDS-UHFFFAOYSA-N 2-(4-methyl-3,4-dihydronaphthalen-2-yl)pyridin-4-amine Chemical compound C=1C2=CC=CC=C2C(C)CC=1C1=CC(N)=CC=N1 SNKWOEPQIIAWDS-UHFFFAOYSA-N 0.000 claims 1
- DLGPEZQGUDCXJM-UHFFFAOYSA-N 2-(5,7-dimethyl-3,4-dihydronaphthalen-2-yl)pyridin-4-amine Chemical compound C=1C2=CC(C)=CC(C)=C2CCC=1C1=CC(N)=CC=N1 DLGPEZQGUDCXJM-UHFFFAOYSA-N 0.000 claims 1
- QVQQJPQHCUCAOD-UHFFFAOYSA-N 2-(6,7-dihydro-1-benzothiophen-5-yl)-5-methylpyridin-4-amine Chemical compound C1=C(N)C(C)=CN=C1C(CC1)=CC2=C1SC=C2 QVQQJPQHCUCAOD-UHFFFAOYSA-N 0.000 claims 1
- VPEVEVRKQIKMEA-UHFFFAOYSA-N 2-(6,7-dihydro-1-benzothiophen-5-yl)pyridin-4-amine Chemical compound NC1=CC=NC(C=2CCC=3SC=CC=3C=2)=C1 VPEVEVRKQIKMEA-UHFFFAOYSA-N 0.000 claims 1
- BKJZTWUBLZGNON-UHFFFAOYSA-N 2-(7-chloro-3,4-dihydronaphthalen-2-yl)-5-methylpyridin-4-amine Chemical compound C1=C(N)C(C)=CN=C1C1=CC2=CC(Cl)=CC=C2CC1 BKJZTWUBLZGNON-UHFFFAOYSA-N 0.000 claims 1
- MTXVPTXXMDUOII-UHFFFAOYSA-N 2-(7-chloro-3,4-dihydronaphthalen-2-yl)-6-ethylpyridin-4-amine Chemical compound CCC1=CC(N)=CC(C=2CCC3=CC=C(Cl)C=C3C=2)=N1 MTXVPTXXMDUOII-UHFFFAOYSA-N 0.000 claims 1
- ZHMNZUJREAWPIV-UHFFFAOYSA-N 2-(7-chloro-3,4-dihydronaphthalen-2-yl)-6-methylpyridin-4-amine Chemical compound CC1=CC(N)=CC(C=2CCC3=CC=C(Cl)C=C3C=2)=N1 ZHMNZUJREAWPIV-UHFFFAOYSA-N 0.000 claims 1
- KADSWFSQJACMOT-UHFFFAOYSA-N 2-(7-chloro-3,4-dihydronaphthalen-2-yl)pyridin-4-amine Chemical compound NC1=CC=NC(C=2CCC3=CC=C(Cl)C=C3C=2)=C1 KADSWFSQJACMOT-UHFFFAOYSA-N 0.000 claims 1
- HROXYBXSZXJQQN-VOTSOKGWSA-N 2-[(e)-2-phenylethenyl]pyridin-4-amine Chemical compound NC1=CC=NC(\C=C\C=2C=CC=CC=2)=C1 HROXYBXSZXJQQN-VOTSOKGWSA-N 0.000 claims 1
- GNTNYOIAUFZGPK-UHFFFAOYSA-N 2-methyl-6-(4-methyl-3,4-dihydronaphthalen-2-yl)pyridin-4-amine Chemical compound C=1C2=CC=CC=C2C(C)CC=1C1=CC(N)=CC(C)=N1 GNTNYOIAUFZGPK-UHFFFAOYSA-N 0.000 claims 1
- JNKAKPOJAADXPI-BQYQJAHWSA-N 4-methyl-6-[(e)-2-phenylethenyl]pyridin-2-amine Chemical compound CC1=CC(N)=NC(\C=C\C=2C=CC=CC=2)=C1 JNKAKPOJAADXPI-BQYQJAHWSA-N 0.000 claims 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- MBKZSODXPUTTHT-UHFFFAOYSA-N 5-methyl-2-(4-methyl-3,4-dihydronaphthalen-2-yl)pyridin-4-amine Chemical compound C=1C2=CC=CC=C2C(C)CC=1C1=CC(N)=C(C)C=N1 MBKZSODXPUTTHT-UHFFFAOYSA-N 0.000 claims 1
- XHUQFKUYBTVYNB-BQYQJAHWSA-N 6-methyl-4-[(e)-2-phenylethenyl]pyridin-2-amine Chemical compound NC1=NC(C)=CC(\C=C\C=2C=CC=CC=2)=C1 XHUQFKUYBTVYNB-BQYQJAHWSA-N 0.000 claims 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- POZGKKTZKLMMIG-UHFFFAOYSA-N [4-amino-6-(3,4-dihydronaphthalen-2-yl)pyridin-2-yl]methanol Chemical compound NC1=CC(CO)=NC(C=2CCC3=CC=CC=C3C=2)=C1 POZGKKTZKLMMIG-UHFFFAOYSA-N 0.000 claims 1
- IMJOZNZWAXXSQG-MDZDMXLPSA-N [6-[(e)-2-phenylethenyl]pyridin-2-yl]methanamine Chemical compound NCC1=CC=CC(\C=C\C=2C=CC=CC=2)=N1 IMJOZNZWAXXSQG-MDZDMXLPSA-N 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/53—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01125765.6 | 2001-10-29 | ||
| EP01125765 | 2001-10-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2004116473A true RU2004116473A (ru) | 2005-11-10 |
Family
ID=8179103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2004116473/04A RU2004116473A (ru) | 2001-10-29 | 2002-10-22 | Производные пиридина в качестве блокаторов подтипа nmda- рецепторов |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US6951875B2 (https=) |
| EP (1) | EP1443926A1 (https=) |
| JP (1) | JP2005511559A (https=) |
| KR (1) | KR100591935B1 (https=) |
| CN (2) | CN1578662A (https=) |
| AR (1) | AR037249A1 (https=) |
| BR (1) | BR0213572A (https=) |
| CA (1) | CA2464888A1 (https=) |
| MX (1) | MXPA04003935A (https=) |
| PL (1) | PL370693A1 (https=) |
| RU (1) | RU2004116473A (https=) |
| WO (1) | WO2003037333A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2717665C2 (ru) * | 2015-04-15 | 2020-03-24 | Ф. Хоффманн-Ля Рош Аг | Пиридопиримидиноны и их применение в качестве модуляторов рецептора n-метил-d-аспартата |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030073712A1 (en) * | 2001-07-23 | 2003-04-17 | Bing Wang | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods |
| EP1802587A4 (en) * | 2004-10-15 | 2010-02-17 | Astrazeneca Ab | SUBSTITUTED AMINO BINDINGS AND THEIR APPLICATIONS |
| WO2006041405A1 (en) * | 2004-10-15 | 2006-04-20 | Astrazeneca Ab | Substituted amino-pyrimidones and uses thereof |
| EP1831170A4 (en) * | 2004-12-14 | 2009-10-14 | Astrazeneca Ab | SUBSTITUTED AMINOPYRIDINES AND THEIR USE |
| CN101360720A (zh) * | 2005-11-15 | 2009-02-04 | 阿斯利康(瑞典)有限公司 | 新颖的2-氨基嘧啶酮衍生物及其用途 |
| WO2007058582A1 (en) * | 2005-11-15 | 2007-05-24 | Astrazeneca Ab | Novel 2-aminopyrimidinone or 2-aminopyridinone derivatives and their use |
| AR058381A1 (es) * | 2005-12-19 | 2008-01-30 | Astrazeneca Ab | Compuestos derivados de 2-aminopiridin-4-onas y una composicion farmaceutica |
| US20090099217A1 (en) * | 2006-04-05 | 2009-04-16 | Astex Therapeutics Ltd. | 2-Aminopyrimidin-4-Ones And Their Use For Treating Or Preventing Alpha Beta-Related Pathologies |
| US8340014B2 (en) | 2007-12-26 | 2012-12-25 | Lg Electronics Inc. | Method for transmitting and receiving signals using multi-band radio frequencies |
| MX344772B (es) * | 2011-01-28 | 2017-01-06 | Univ Kentucky Res Found | Analogos de estilbeno y metodos para tratar cancer. |
| US8993258B2 (en) * | 2012-06-12 | 2015-03-31 | The University Of Connecticut | Fluorinated voltage sensitive dyes, preparation thereof, and optical methods of use |
| US10300155B2 (en) | 2015-12-31 | 2019-05-28 | Washington University | Alpha-synuclein ligands |
| US10449186B2 (en) | 2017-06-21 | 2019-10-22 | University Of Kentucky Research Foundation | Phenylethynyl-substituted benzenes and heterocycles for the treatment of cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5648369A (en) | 1991-11-20 | 1997-07-15 | University Of Kentucky Research Foundation | Aminoalkylpyridine compounds which are useful as anitconvulsant drugs, excitatory amino acid inhibitors and NMDA sigma receptor antagonists |
| CA2187214C (en) * | 1994-04-06 | 2002-03-12 | Hiroyoshi Hidaka | Aminostilbazole derivative and medicine |
| PT885004E (pt) | 1996-03-08 | 2002-08-30 | Hoffmann La Roche | Utilizacao de derivados de 4-fenil-3,6-di-hidro-2h-piridilo como bloqueadores dos subtipos dos receptores nmda |
| US5869676A (en) | 1997-05-15 | 1999-02-09 | Vion Pharmaceuticals, Inc. | Process for the synthesis of ribonucleotide reductase inhibitors 3-AP and 3-AMP |
| TW544448B (en) * | 1997-07-11 | 2003-08-01 | Novartis Ag | Pyridine derivatives |
| TWI254043B (en) | 1999-06-08 | 2006-05-01 | Hoffmann La Roche | Ethanesulfonyl-piperidine derivatives having good affinity to N-methyl-D-aspartate (NMDA) receptor |
| EP1070708B1 (en) | 1999-07-21 | 2004-01-14 | F. Hoffmann-La Roche Ag | Triazole derivatives |
| DK1088818T3 (da) | 1999-10-01 | 2005-03-14 | Hoffmann La Roche | Quinolin-4-yl-derivater |
-
2002
- 2002-10-21 US US10/277,002 patent/US6951875B2/en not_active Expired - Fee Related
- 2002-10-22 KR KR1020047006334A patent/KR100591935B1/ko not_active Expired - Fee Related
- 2002-10-22 CN CNA028214242A patent/CN1578662A/zh active Pending
- 2002-10-22 EP EP02782972A patent/EP1443926A1/en not_active Withdrawn
- 2002-10-22 PL PL02370693A patent/PL370693A1/xx not_active Application Discontinuation
- 2002-10-22 RU RU2004116473/04A patent/RU2004116473A/ru not_active Application Discontinuation
- 2002-10-22 JP JP2003539677A patent/JP2005511559A/ja active Pending
- 2002-10-22 WO PCT/EP2002/011782 patent/WO2003037333A1/en not_active Ceased
- 2002-10-22 BR BR0213572-8A patent/BR0213572A/pt not_active IP Right Cessation
- 2002-10-22 MX MXPA04003935A patent/MXPA04003935A/es unknown
- 2002-10-22 CN CNA2006100670615A patent/CN1837195A/zh active Pending
- 2002-10-22 CA CA002464888A patent/CA2464888A1/en not_active Abandoned
- 2002-10-25 AR ARP020104048A patent/AR037249A1/es not_active Application Discontinuation
-
2003
- 2003-09-26 US US10/672,950 patent/US7034044B2/en not_active Expired - Fee Related
-
2005
- 2005-10-21 US US11/255,526 patent/US20060058354A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2717665C2 (ru) * | 2015-04-15 | 2020-03-24 | Ф. Хоффманн-Ля Рош Аг | Пиридопиримидиноны и их применение в качестве модуляторов рецептора n-метил-d-аспартата |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20050039710A (ko) | 2005-04-29 |
| BR0213572A (pt) | 2004-10-26 |
| US6951875B2 (en) | 2005-10-04 |
| US20060058354A1 (en) | 2006-03-16 |
| CA2464888A1 (en) | 2003-05-08 |
| EP1443926A1 (en) | 2004-08-11 |
| CN1837195A (zh) | 2006-09-27 |
| PL370693A1 (en) | 2005-05-30 |
| JP2005511559A (ja) | 2005-04-28 |
| CN1578662A (zh) | 2005-02-09 |
| MXPA04003935A (es) | 2004-06-18 |
| US20030144525A1 (en) | 2003-07-31 |
| AR037249A1 (es) | 2004-11-03 |
| US7034044B2 (en) | 2006-04-25 |
| KR100591935B1 (ko) | 2006-06-22 |
| US20040068118A1 (en) | 2004-04-08 |
| WO2003037333A1 (en) | 2003-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI844568B (zh) | 抑制shp2活性化合物之製造方法、及由酸加成產生之產物 | |
| CN110240596B (zh) | 用于治疗hbv感染的治疗剂 | |
| RU2004116473A (ru) | Производные пиридина в качестве блокаторов подтипа nmda- рецепторов | |
| JP7121660B2 (ja) | 癌を処置するためのｅｚｈ２阻害剤の使用 | |
| JP2021534124A (ja) | 癌治療用ｐｔｐｎ１１（ｓｈｐ２）阻害剤としての６−（４−アミノ−３−メチル−２−オキサ−８−アザスピロ［４．５］デカン−８−イル）−３−（２，３−ジクロロフェニル）−２−メチルピリミジン−４（３ｈ）−オン誘導体及び関連化合物 | |
| JP6648137B2 (ja) | ヘテロ環式誘導体およびその使用 | |
| KR20190080897A (ko) | 치환된 피리디논 함유 트리시클릭 화합물, 및 그의 사용 방법 | |
| JP5855250B2 (ja) | イミダゾオキサジン化合物による抗腫瘍効果増強剤 | |
| KR20020063934A (ko) | 코르티코트로핀 방출 인자 길항제 | |
| KR20210121044A (ko) | 치환된 폴리사이클릭 카복실산, 이의 유사체, 및 이의 사용 방법 | |
| JP2007534695A5 (https=) | ||
| KR20200058411A (ko) | 인터페론 유전자 조절인자의 자극제로서의 환식 다이-뉴클레오타이드 | |
| EA025863B1 (ru) | Карбазолкарбоксамидные соединения | |
| CA2668997A1 (en) | 4-cyanophenylamino-substituted bicyclic heterocyclic compounds as hiv inhibitors | |
| CN108025191A (zh) | 治疗癌症的方法 | |
| EP4323349A1 (en) | Isoindolinone amide compounds useful to treat diseases associated with gspt1 | |
| WO2022214691A1 (en) | Deuterated dhodh inhibitors | |
| RU2004117595A (ru) | Производные пиридина в качестве лигандов рецептора nmda | |
| JP2005511559A5 (https=) | ||
| US20150087886A1 (en) | Novel bifunctional metnase/intnase inhibitors and related compositions and methods of treatment of cancer | |
| JP5922157B2 (ja) | （−）−フペルジンａの工程及び関連組成物並びに治療法 | |
| JPWO2020243519A5 (https=) | ||
| RU2002103301A (ru) | Производные индола | |
| WO2021097075A1 (en) | Substituted isoindolonyl 2,2'-bipyrimidinyl compounds, analogues thereof, and methods using same | |
| JP2005504734A5 (https=) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20070312 |